Biosimilar Antibodies

Efprezimod alfa Biosimilar – Research Grade, ProteoGenix, PX-TA2458-100

Efungumab Biosimilar – Anti-HSP91 homolog mAb – Research Grade, ProteoGenix, PX-TA1127

Description of Efungumab Biosimilar - Anti-HSP91 homolog mAb - Research Grade Introduction to Efungumab Biosimilar – An Anti-HSP91 Homolog mAb Efungumab Biosimilar is a monoclonal antibody (mAb) that has been developed as a biosimilar version of the original drug, Efungumab. This antibody specifically targets the heat shock protein 90 (HSP90) homolog, which has been identified as a potential therapeutic target for various diseases. In this article, we will provide a scientific description of Efungumab Biosimilar, including its structure, activity, and potential applications. Structure of Efungumab Biosimilar Efungumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the target antigen, while the constant region plays a role in effector functions such as complement activation and antibody-dependent cellular cytotoxicity. Activity of Efungumab Biosimilar Efungumab Biosimilar specifically targets the HSP90 homolog, which is a highly conserved protein that plays a crucial role in cell survival and proliferation. This protein is overexpressed in many types of cancer, making it an attractive therapeutic target. By binding to the HSP90 homolog, Efungumab Biosimilar inhibits its activity, leading to the inhibition of cell growth and survival. This mechanism of action makes it a promising candidate for the treatment of various cancers. Applications of Efungumab Biosimilar Efungumab Biosimilar has shown promising results in preclinical studies for the treatment of various types of cancer, including breast, lung, and prostate cancer. It has also been evaluated in clinical trials for the treatment of multiple myeloma, a type of blood cancer. In addition to its potential as an anti- cancer therapy, Efungumab Biosimilar has also shown potential in the treatment of autoimmune diseases, as the HSP90 homolog has been implicated in the pathogenesis of these diseases. Mechanism of Action of Efungumab Biosimilar As mentioned earlier, Efungumab Biosimilar exerts its therapeutic effects by targeting the HSP90 homolog. This protein is known to play a critical role in the proper folding and stabilization of many cellular proteins, including oncogenic proteins in cancer cells. By binding to the HSP90 homolog, Efungumab Biosimilar disrupts its chaperone function, leading to the degradation of these oncogenic proteins and ultimately inhibiting the growth and survival of cancer cells. Advantages of Efungumab Biosimilar as a Therapeutic Antibody Efungumab Biosimilar has several advantages over other therapeutic antibodies currently available in the market. Firstly, being a biosimilar, it has a similar structure and mechanism of action to the original drug, making it a more cost-effective option. Additionally, its humanized structure reduces the risk of immunogenicity and improves its safety profile. Moreover, its high specificity for the HSP90 homolog makes it a targeted therapy, minimizing potential side effects. Conclusion In conclusion, Efungumab Biosimilar is a promising therapeutic antibody that specifically targets the HSP90 homolog, a protein overexpressed in many types of cancer. Its mechanism of action involves inhibiting the chaperone function of the HSP90 homolog, leading to the degradation of oncogenic proteins and inhibition of cancer cell growth. With its potential applications in various diseases and advantages as a therapeutic antibody, Efungumab Biosimilar holds great promise in the field of biopharmaceuticals.

Elezanumab Biosimilar – Anti-RGMA mAb – Research Grade, ProteoGenix, PX-TA1439

Description of Elezanumab Biosimilar - Anti-RGMA mAb - Research Grade General information on Anti-RGMA[Homo sapiens] (Elezanumab) Monoclonal Antibody Elezanumab is investigated in the treatment of Progressive Forms of Multiple Sclerosis.

Elipunercept Biosimilar – Research Grade, ProteoGenix, PX-TA2474-100

Elotuzumab Biosimilar – Anti-SLAMF7, CD319 mAb – Research Grade, ProteoGenix, PX-TA1206

Description of Elotuzumab Biosimilar - Anti-SLAMF7, CD319 mAb - Research Grade Introduction Elotuzumab Biosimilar, also known as Anti-SLAMF7 or CD319 monoclonal antibody, is a research grade therapeutic antibody that is currently being studied for its potential use in the treatment of multiple myeloma. This antibody specifically targets the SLAMF7 protein, which is overexpressed in multiple myeloma cells, making it a promising therapeutic target. Structure of Elotuzumab Biosimilar Elotuzumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from human cells and has been modified to have a high affinity for SLAMF7. It is composed of two heavy chains and two light chains, each with a specific sequence of amino acids that determine its binding specificity. The antibody has a molecular weight of approximately 148 kDa and a half-life of 14 days. Mechanism of Action The primary mechanism of action of Elotuzumab Biosimilar is through its binding to SLAMF7 on the surface of multiple myeloma cells. This binding leads to the activation of natural killer (NK) cells and macrophages, which are part of the body’s immune system and play a crucial role in fighting cancer cells. The activated NK cells and macrophages then target and destroy the multiple myeloma cells, leading to tumor regression. Research and Clinical Trials Elotuzumab Biosimilar has been extensively studied in preclinical and clinical trials for its potential use in the treatment of multiple myeloma. In a phase I clinical trial, it was found to be well-tolerated and showed promising results in terms of its anti-tumor activity. Subsequent phase II and III trials have also shown significant improvements in progression-free survival and overall response rates when Elotuzumab Biosimilar was used in combination with other standard multiple myeloma therapies. Current and Potential Applications Currently, Elotuzumab Biosimilar is being investigated as a potential treatment for relapsed or refractory multiple myeloma, either as a monotherapy or in combination with other therapies. It has also shown promise in the treatment of newly diagnosed multiple myeloma, particularly in combination with lenalidomide and dexamethasone. In addition to multiple myeloma, Elotuzumab Biosimilar is also being studied for its potential use in other types of cancers, such as Waldenstrom macroglobulinemia and non-Hodgkin’s lymphoma, where SLAMF7 is also overexpressed. Conclusion In summary, Elotuzumab Biosimilar is a promising therapeutic antibody that specifically targets SLAMF7, a protein that is overexpressed in multiple myeloma cells. Its mechanism of action involves activating the body’s immune system to target and destroy cancer cells. With ongoing research and clinical trials, it has the potential to become a valuable treatment option for multiple myeloma and other cancers.

Elranatamab Biosimilar – Anti-TNFRSF17;CD3E mAb – Research Grade, ProteoGenix, PX-TA1832

Description of Elranatamab Biosimilar - Anti-TNFRSF17;CD3E mAb - Research Grade Introduction Elranatamab Biosimilar, also known as Anti-TNFRSF17,CD3E mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody elotuzumab. It is a promising therapeutic agent for the treatment of multiple myeloma and other B-cell malignancies. In this article, we will discuss the structure, activity, and potential applications of Elranatamab Biosimilar in detail. Structure of Elranatamab Biosimilar Elranatamab Biosimilar is a chimeric monoclonal antibody that is composed of a human immunoglobulin G1 (IgG1) constant region and a mouse variable region. The variable region of the antibody is derived from the hybridoma cell line that produces elotuzumab. This structure allows Elranatamab Biosimilar to bind to the same target as elotuzumab, but with a different mechanism of action. Activity of Elranatamab Biosimilar Elranatamab Biosimilar targets two proteins on the surface of B-cells: TNFRSF17 and CD3E. TNFRSF17, also known as B-cell maturation antigen (BCMA), is a cell surface receptor that is overexpressed on multiple myeloma cells. CD3E is a component of the T-cell receptor complex that is involved in T-cell activation. By targeting both TNFRSF17 and CD3E, Elranatamab Biosimilar has a dual mechanism of action. The binding of Elranatamab Biosimilar to TNFRSF17 on multiple myeloma cells leads to the activation of signaling pathways that induce cell death. This is achieved through the recruitment of natural killer cells and macrophages to the tumor site, as well as the activation of the complement system. On the other hand, the binding of Elranatamab Biosimilar to CD3E on T-cells leads to their activation and proliferation, which further enhances the immune response against cancer cells. Applications of Elranatamab Biosimilar Elranatamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of multiple myeloma and other B-cell malignancies. It is expected to have similar efficacy and safety as elotuzumab, but at a lower cost due to its biosimilar nature. In addition to its potential use as a monotherapy, Elranatamab Biosimilar can also be combined with other therapies to improve treatment outcomes. For example, it can be used in combination with proteasome inhibitors or immunomodulatory drugs to enhance their anti-tumor effects. It can also be combined with other monoclonal antibodies, such as daratumumab, to target multiple pathways involved in the growth and survival of cancer cells. Conclusion In summary, Elranatamab Biosimilar is a promising therapeutic agent for the treatment of multiple myeloma and other B-cell malignancies. Its unique structure and dual mechanism of action make it a valuable addition to the current treatment options for these diseases. As clinical trials continue to evaluate its safety and efficacy, Elranatamab Biosimilar has the potential to become a widely used therapy for patients with these types of cancer.

Elritercept Biosimilar – Anti-ACVR2 fusion protein – Research Grade, ProteoGenix, PX-TA1991

Description of Elritercept Biosimilar - Anti-ACVR2 fusion protein - Research Grade Introduction Elritercept Biosimilar is a novel fusion protein that has gained significant attention in the scientific community due to its potential therapeutic applications. It is an anti-ACVR2 fusion protein that has been developed as a biosimilar of the original Elritercept protein, which has shown promising results in clinical trials for the treatment of various diseases. Structure of Elritercept Biosimilar Elritercept Biosimilar is a fusion protein composed of two distinct parts: an antibody and a therapeutic target. The antibody component is derived from the original Elritercept protein, which is a monoclonal antibody that specifically binds to the ACVR2 protein. The therapeutic target component is a fusion protein consisting of the extracellular domain of the ACVR2 protein fused to a human IgG1 Fc fragment. Activity of Elritercept Biosimilar The main activity of Elritercept Biosimilar is its ability to inhibit the activity of the ACVR2 protein. ACVR2 is a type II receptor for the transforming growth factor-beta (TGF-β) family of proteins, which play important roles in various cellular processes such as cell proliferation, differentiation, and apoptosis. Dysregulation of the TGF-β signaling pathway has been linked to the development and progression of various diseases, including cancer, fibrosis, and autoimmune disorders. Elritercept Biosimilar works by binding to the ACVR2 protein, thereby preventing the binding of TGF-β ligands and inhibiting downstream signaling pathways. Applications of Elritercept Biosimilar Elritercept Biosimilar has potential applications in the treatment of various diseases where dysregulation of the TGF-β signaling pathway is involved. One of the most promising applications is in the treatment of cancer. Studies have shown that TGF-β signaling plays a crucial role in tumor growth, invasion, and metastasis. By inhibiting the activity of ACVR2, Elritercept Biosimilar has the potential to slow down or even halt the progression of cancer. Another potential application of Elritercept Biosimilar is in the treatment of fibrosis. TGF-β signaling is known to contribute to the development of fibrosis, which is characterized by excessive deposition of extracellular matrix proteins in various tissues. By inhibiting ACVR2, Elritercept Biosimilar can potentially prevent the development of fibrosis and even reverse its progression. In addition, Elritercept Biosimilar may also have therapeutic potential in autoimmune disorders. TGF-β signaling has been implicated in the pathogenesis of various autoimmune diseases, and inhibiting this pathway with Elritercept Biosimilar may help to alleviate symptoms and improve disease outcomes. Research Grade Elritercept Biosimilar Elritercept Biosimilar is currently being developed as a research-grade protein for use in preclinical studies and research purposes. This grade of the protein is highly purified and has been extensively characterized to ensure consistency and quality. It is intended for use in in vitro and in vivo studies to further investigate the potential therapeutic applications of Elritercept Biosimilar. Conclusion In summary, Elritercept Biosimilar is a promising fusion protein that has the potential to be used as a therapeutic agent for the treatment of various diseases. Its unique structure, activity, and applications make it a valuable tool for further research and development in the field of TGF-β signaling and its role in disease. As research on this protein continues, it is hoped that Elritercept Biosimilar will eventually become a valuable treatment option for patients in need.

Eluvixtamab Biosimilar – Anti-CD33;CD3E mAb – Research Grade, ProteoGenix, PX-TA1662

Description of Eluvixtamab Biosimilar - Anti-CD33;CD3E mAb - Research Grade Eluvixtamab Biosimilar – Anti-CD33,CD3E mAb – Research Grade Introduction Eluvixtamab Biosimilar is a novel monoclonal antibody (mAb) that targets both CD33 and CD3E, two important proteins involved in the immune response. This research grade antibody has shown promising results in pre-clinical studies and is currently being evaluated for its potential therapeutic applications. Structure of Eluvixtamab Biosimilar Eluvixtamab Biosimilar is a chimeric antibody, meaning it is composed of both human and mouse components. The variable region of the antibody is derived from a mouse mAb that specifically binds to CD33 and CD3E, while the constant region is humanized to reduce immunogenicity. This structure allows for high specificity and affinity towards the target proteins. Mechanism of Action Eluvixtamab Biosimilar works by binding to both CD33 and CD3E on the surface of immune cells. CD33 is a protein found on myeloid cells, such as monocytes and macrophages, while CD3E is a protein found on T cells. By binding to both proteins, Eluvixtamab Biosimilar brings these two types of immune cells in close proximity, leading to enhanced immune response and cell death of target cells. Therapeutic Applications Eluvixtamab Biosimilar has shown potential in the treatment of various diseases, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other hematological malignancies. CD33 is overexpressed on the surface of AML cells, making it an ideal target for this antibody. By binding to CD33, Eluvixtamab Biosimilar can induce cell death and inhibit the growth of AML cells. Additionally, the binding of Eluvixtamab Biosimilar to CD3E can activate T cells, leading to a stronger immune response against cancer cells. Advantages of Eluvixtamab Biosimilar Compared to other anti-CD33 antibodies, Eluvixtamab Biosimilar has several advantages. Its chimeric structure allows for high specificity and affinity towards the target proteins, while its humanized constant region reduces the risk of immunogenicity. Additionally, the ability to target both CD33 and CD3E makes it a more potent therapeutic agent compared to antibodies that only target one protein. Conclusion In conclusion, Eluvixtamab Biosimilar is a novel monoclonal antibody that targets both CD33 and CD3E, two important proteins involved in the immune response. Its unique structure and mechanism of action make it a promising therapeutic agent for the treatment of various diseases, particularly in the field of oncology. Further research and clinical trials are needed to fully evaluate the potential of Eluvixtamab Biosimilar in improving patient outcomes.

Emapalumab Biosimilar – Anti-IFNG mAb – Research Grade, ProteoGenix, PX-TA1450

Description of Emapalumab Biosimilar - Anti-IFNG mAb - Research Grade The Structure of Emapalumab Biosimilar – Anti-IFNG mAb Emapalumab Biosimilar, also known as Anti-IFNG monoclonal antibody (mAb), is a biologic drug that is designed to mimic the function of the natural antibody, interferon-gamma (IFN-gamma). It is a recombinant humanized IgG1 kappa monoclonal antibody that specifically targets and binds to IFN-gamma, a cytokine that plays a crucial role in the immune response. The structure of Emapalumab Biosimilar is composed of two heavy chains and two light chains, each with a molecular weight of approximately 50 kDa. The heavy chains consist of four constant regions (C1-C4) and one variable region (VH), while the light chains consist of two constant regions (C1, C2) and one variable region (VL). The variable regions of both the heavy and light chains are responsible for the specificity and binding affinity of Emapalumab Biosimilar to IFN-gamma. The Activity of Emapalumab Biosimilar – Anti-IFNG mAb Emapalumab Biosimilar works by binding to IFN-gamma and preventing it from interacting with its receptors on the surface of immune cells. This leads to a decrease in the activity of IFN-gamma, which is known to play a role in various inflammatory and autoimmune diseases. One of the key activities of Emapalumab Biosimilar is its ability to block the production of pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). These cytokines are known to contribute to the pathogenesis of several autoimmune diseases, and by inhibiting their production, Emapalumab Biosimilar helps to reduce inflammation and disease progression. In addition, Emapalumab Biosimilar also enhances the activity of regulatory T cells (Tregs), which are responsible for maintaining immune tolerance and preventing excessive immune responses. By increasing the number and function of Tregs, Emapalumab Biosimilar helps to restore immune balance and prevent autoimmune reactions. The Applications of Emapalumab Biosimilar – Anti-IFNG mAb Emapalumab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various autoimmune and inflammatory diseases. It is currently being developed as a potential therapeutic option for the following conditions: Rheumatoid Arthritis (RA) RA is a chronic autoimmune disease characterized by inflammation and destruction of joints. Emapalumab Biosimilar has shown to be effective in reducing joint inflammation and preventing joint damage in animal models of RA. In a phase II clinical trial, Emapalumab Biosimilar showed significant improvement in disease activity and symptoms in patients with RA. Inflammatory Bowel Disease (IBD) IBD, which includes Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder of the gastrointestinal tract. Emapalumab Biosimilar has been shown to reduce inflammation and improve symptoms in animal models of IBD. In a phase II clinical trial, Emapalumab Biosimilar demonstrated significant improvement in clinical remission and endoscopic healing in patients with moderate to severe Crohn’s disease. Systemic Lupus Erythematosus (SLE) SLE is a systemic autoimmune disease that can affect multiple organs and tissues. Emapalumab Biosimilar has been shown to reduce inflammation and prevent tissue damage in animal models of SLE. In a phase II clinical trial, Emapalumab Biosimilar showed promising results in reducing disease activity and improving symptoms in patients with SLE. Psoriasis Psoriasis is a chronic autoimmune skin disorder characterized by red, scaly patches on the skin. Emapalumab Biosimilar has been shown to reduce skin inflammation and improve symptoms in animal models of psoriasis. In a phase

Emaretamig Biosimilar – Research Grade, ProteoGenix, PX-TA2475-100